Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program

被引：81

作者：

Ascierto, Paolo Antonio ^{[1
]}

Simeone, Ester ^{[1
]}

Sileni, Vanna Chiarion ^{[2
]}

Del Vecchio, Michele ^{[3
]}

Marchetti, Paolo ^{[4
,5
]}

Cappellini, Gian Carlo Antonini ^{[4
]}

Ridolfi, Ruggero ^{[6
]}

de Rosa, Francesco ^{[6
]}

Cognetti, Francesco ^{[7
]}

Ferraresi, Virginia ^{[7
]}

Testori, Alessandro ^{[8
]}

Queirolo, Paola ^{[9
]}

Bernengo, Maria Grazia ^{[10
]}

Guida, Michele ^{[11
]}

Galli, Luca ^{[12
]}

Mandala, Mario ^{[13
]}

Cimminiello, Carolina ^{[14
]}

Rinaldi, Gaetana ^{[15
]}

Carnevale-Schianca, Fabrizio ^{[16
]}

Maio, Michele ^{[17
]}

机构：

[1] Ist Nazl Tumori Fdn G Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, I-80131 Naples, Italy

[2] Veneto Inst Oncol IOV IRCCS, Melanoma Canc Unit, Padua, Italy

[3] Natl Canc Inst, I-20133 Milan, Italy

[4] Dermopath Inst Immaculate IDI IRCCS, Rome, Italy

[5] Univ Roma La Sapienza, St Andrea Hosp, I-00185 Rome, Italy

[6] Romagna Natl Canc Inst, Immunotherapy Unit, Meldola, Italy

[7] Regina Elena Inst Canc Res, Dept Med Oncol A, Rome, Italy

[8] European Inst Oncol, Melanoma Div, Milan, Italy

[9] San Martino Hosp, Natl Inst Canc Res, Genoa, Italy

[10] Univ Hosp St John Baptist, Turin, Italy

[11] Natl Canc Res Ctr, Dept Med Oncol, Bari, Italy

[12] Univ Hosp S Chiara, Div Med Oncol, Pisa, Italy

[13] Papa Giovanni XXIII Hosp, Med Oncol Unit, Bergamo, Italy

[14] Hosp San Raffaele, Unit Immunobiotherapy Melanoma, I-20132 Milan, Italy

[15] Paolo Giaccone Polyclin Univ Hosp, Palermo, Italy

[16] Piedmont Oncol Fdn, Inst Canc Res & Treatment, Candiolo, Italy

[17] Univ Hosp Siena, Ist Toscano Tumori, Siena, Italy

来源：

CANCER INVESTIGATION | 2014年 / 32卷 / 04期

关键词：

Cutaneous melanoma; Tumor immunology; Treatment; Molecular biology; FOLLOW-UP; VEMURAFENIB; THERAPY;

D O I：

10.3109/07357907.2014.885984

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Of 93 patients with pretreated, BRAF(V600) mutation-positive advanced melanoma who received vemurafenib or dabrafenib before (n=45) or after (n=48) treatment with ipilimumab 3 mg/kg, median overall survival (mOS) from first treatment was 9.9 and 14.5months, respectively. Among patients treated with a BRAF inhibitor first, mOS from the end of BRAF inhibition was 1.2 months for those who did not complete ipilimumab treatment as per protocol, compared with 12.7 months for those who did (p < .001). Prospective, randomized studies are required to determine the optimal sequencing of ipilimumab and BRAF inhibitors in patients with BRAF-mutated metastatic melanoma.

引用

页码：144 / 149

页数：6

共 23 条

[1]

Ackerman A, 2012, J CLIN ONCOL, V30

[2]

Adjei AA, 2013, J CLIN ONCOL, V31

[3]

[Anonymous], J CLIN ONCOL S

[4]

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study [J].

Ascierto, Paolo A. ;

Schadendorf, Dirk ;

Berking, Carola ;

Agarwala, Sanjiv S. ;

van Herpen, Carla M. L. ;

Queirolo, Paola ;

Blank, Christian U. ;

Hauschild, Axel ;

Beck, J. Thaddeus ;

St-Pierre, Annie ;

Niazi, Faiz ;

Wandel, Simon ;

Peters, Malte ;

Zubel, Angela ;

Dummer, Reinhard .

LANCET ONCOLOGY, 2013, 14 (03) :249-256

[5]

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use [J].

Ascierto, Paolo A. ;

Simeone, Ester ;

Giannarelli, Diana ;

Grimaldi, Antonio M. ;

Romano, Anna ;

Mozzillo, Nicola .

JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10

[6]

Do BRAF inhibitors select for populations with different disease progression kinetics? [J].

Ascierto, Paolo Antonio ;

Simeone, Ester ;

Grimaldi, Antonio Maria ;

Curvietto, Marcello ;

Esposito, Assunta ;

Palmieri, Giuseppe ;

Mozzillo, Nicola .

JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11

[7]

Final Version of 2009 AJCC Melanoma Staging and Classification [J].

Balch, Charles M. ;

Gershenwald, Jeffrey E. ;

Soong, Seng-jaw ;

Thompson, John F. ;

Atkins, Michael B. ;

Byrd, David R. ;

Buzaid, Antonio C. ;

Cochran, Alistair J. ;

Coit, Daniel G. ;

Ding, Shouluan ;

Eggermont, Alexander M. ;

Flaherty, Keith T. ;

Gimotty, Phyllis A. ;

Kirkwood, John M. ;

McMasters, Kelly M. ;

Mihm, Martin C., Jr. ;

Morton, Donald L. ;

Ross, Merrick I. ;

Sober, Arthur J. ;

Sondak, Vernon K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6199-6206

[8]

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].

Chapman, Paul B. ;

Hauschild, Axel ;

Robert, Caroline ;

Haanen, John B. ;

Ascierto, Paolo ;

Larkin, James ;

Dummer, Reinhard ;

Garbe, Claus ;

Testori, Alessandro ;

Maio, Michele ;

Hogg, David ;

Lorigan, Paul ;

Lebbe, Celeste ;

Jouary, Thomas ;

Schadendorf, Dirk ;

Ribas, Antoni ;

O'Day, Steven J. ;

Sosman, Jeffrey A. ;

Kirkwood, John M. ;

Eggermont, Alexander M. M. ;

Dreno, Brigitte ;

Nolop, Keith ;

Li, Jiang ;

Nelson, Betty ;

Hou, Jeannie ;

Lee, Richard J. ;

Flaherty, Keith T. ;

McArthur, Grant A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516

[9]

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma [J].

Cooper, Zachary A. ;

Frederick, Dennie T. ;

Ahmed, Zain ;

Wargo, Jennifer A. .

ONCOIMMUNOLOGY, 2013, 2 (05)

[10]

Fisher R, 2012, PIGMENT CELL MELANOM, V25

← 1 2 3 →